Prognostic Significance of Plasma High-Sensitivity C-Reactive Protein in Patients With Hypertrophic Cardiomyopathy.
Elevated high-sensitivity C-reactive protein (hsCRP) has been associated with increased risks of adverse outcomes of various cardiovascular diseases. The relationship between hsCRP and the prognosis of hypertrophic cardiomyopathy remains to be evaluated.



The study used an observational cohort methodology. A total of 490 patients were enrolled in the Fuwai Hospital from 2001 to 2011 and were followed for 3.7±2.0 years. According to the risk category of hsCRP, subjects in the high hsCRP group (>3.0 mg/L) had a higher risk of developing adverse events than the low hsCRP group (<1.0 mg/L): cardiovascular death (adjusted hazard ratios[HR] 5.41, 95% CI 1.96-14.93, P=0.001), all-cause mortality (adjusted HR 4.78, 95% CI 1.99-11.47, P<0.001), sudden cardiac death (adjusted HR 11.29, 95% CI 1.38-92.20, P=0.024), and heart failure-related death (adjusted HR 4.38, 95% CI 1.15-16.60, P=0.030). Similarly, the continuous variable of hsCRP was also an independent predictor for adverse outcomes: cardiovascular death (adjusted HR 1.15, 95% CI 1.06-1.25, P=0.001), all-cause mortality (adjusted HR 1.17, 95% CI 1.09-1.26, P<0.001), sudden cardiac death (adjusted HR 1.20, 95% CI 1.06-1.36, P=0.003), and heart failure-related death (adjusted HR 1.15, 95% CI 1.02-1.30, P=0.020).



Our results indicate that elevated plasma hsCRP is associated with increased risk for adverse outcomes in patients with hypertrophic cardiomyopathy.
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.|Department of Cardiovascular Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China.
Ling
L
Zhu
Department of Cardiovascular Internal Medicine, Hypertension Center, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Shaanxi, China.
Yubao
Y
Zou
Department of ICU, China Meitan General Hospital, Beijing, China.
Yilu
Y
Wang
Department of Cardiovascular Internal Medicine, Hypertension Center, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Shaanxi, China.
Xiaoliang
X
Luo
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Kai
K
Sun
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hu
H
Wang
Department of Cardiovascular Internal Medicine, Hypertension Center, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Shaanxi, China.
Lei
L
Jia
Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Yan
Y
Liu
Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Juan
J
Zou
Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Zuyi
Z
Yuan
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Rutai
R
Hui
Department of Cardiovascular Internal Medicine, Hypertension Center, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Shaanxi, China.
Lianming
L
Kang
Department of Cardiovascular Internal Medicine, Hypertension Center, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Shaanxi, China lsongqd@yahoo.com jzwang@hotmail.com.
Lei
L
Song
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China lsongqd@yahoo.com jzwang@hotmail.com.
Jizheng
J
Wang
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D002312:Cardiomyopathy, Hypertrophic / Q000097:blood* / Q000401:mortality; D002681:China / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate / Q000639:trends; D055815:Young Adult
D015415:Biomarkers; D002097:C-Reactive Protein
cardiovascular death; high‐sensitivity C‐reactive protein; hypertrophic cardiomyopathy; prognosis